Plasma cell-directed therapy for rituximab-refractory PLA2R+ membranous nephropathy
Nephrol Dial Transplant
.
2023 Nov 30;38(12):2851-2853.
doi: 10.1093/ndt/gfad135.
Authors
Sofiane Salhi
1
,
David Ribes
1
,
Françoise Fortenfant
2
,
Stanislas Faguer
1
3
4
Affiliations
1
Department of Organ Transplantation, National Reference Centre for Rare Kidney Diseases - SORARE, University Hospital of Toulouse, Toulouse, France.
2
Laboratory of Immunology, University Hospital of Toulouse, Toulouse, France.
3
University Paul Sabatier - Toulouse 3, Faculty of Medicine, Toulouse, France.
4
INSERM UMR 1297, Institute of Metabolic and Cardiovascular Diseases, Team 'Kidney Diseases: biomarkers, prevention and treatment', Toulouse, France.
PMID:
37401153
DOI:
10.1093/ndt/gfad135
No abstract available
MeSH terms
Autoantibodies
Glomerulonephritis, Membranous* / drug therapy
Humans
Plasma Cells
Receptors, Phospholipase A2
Rituximab / therapeutic use
Substances
Rituximab
Autoantibodies
Receptors, Phospholipase A2
Grants and funding
University Hospital of Toulouse
Institutional Axis of Research TImE